<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04537962</url>
  </required_header>
  <id_info>
    <org_study_id>4172-20</org_study_id>
    <nct_id>NCT04537962</nct_id>
  </id_info>
  <brief_title>Salivary SARS-CoV-2 Load of Covid-19 Patients After Oral Antimicrobial Solutions and Dentifrices</brief_title>
  <official_title>Avaliação da Carga do vírus SARS-CoV-2 na Cavidade Oral e na Saliva após desinfecção Com soluções Antimicrobianas Orais e dentifrícios.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Israelita Albert Einstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Colgate Palmolive</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Israelita Albert Einstein</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to analyze if the use of oral antimicrobial solutions and&#xD;
      dentifricies are able to reduce the SARS-CoV-2 load in the saliva and oral mucosa. It will be&#xD;
      allocated hospitalized patients positive for SARS-CoV-2 (confirmed by RT-PCR of nasopharynx&#xD;
      swab tests) and with signs and symptoms of COVID-19. These patients will be divided into two&#xD;
      groups: patients enrolled in negative pressure rooms (NPR), and patients enrolled in&#xD;
      intensive care units (ICU) with orotracheal intubation. These two groups will receive&#xD;
      interventions with oral antimicrobial solutions or dentifrices, containing different&#xD;
      compounds. Saliva and oral mucosa swabs will be collected before the intervention,&#xD;
      immediately after the intervention, and after 30min and 1h. The primary outcome is to verify&#xD;
      if these products can reduce the SARS-CoV-2 load in the saliva and oral mucosa at these time&#xD;
      periods, detected by the measurement of the viral load and the fold-reduction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each group of patients will receive specific interventions, as follows:&#xD;
&#xD;
      NPR group (n=60) - three interventions with different mouthwashes solutions (12 patients in&#xD;
      each intervention): 1) 0.12% chlorhexidine solution (Colgate Periogard®); 2) mouthwash with&#xD;
      1.5% hydrogen peroxide solution (Colgate Peroxyl®); 3) mouthwash with 0.075% cetylpyridinium&#xD;
      chloride solution (Colgate Total 12®); 4) 1.5% hydrogen peroxide solution plus 0.12%&#xD;
      chlorhexidine solution (Colgate Peroxyl® followed by Colgate Periogard®).&#xD;
&#xD;
      The interventions will be compared with a Placebo, which will be a mouthwash with distilled&#xD;
      water (n=12).&#xD;
&#xD;
      NPR group (n=90) - three interventions with different dentifrices (30 patients in each&#xD;
      intervention): 1) dentifrice containing only 1.1% fluoride, water, glycerin, cellulose,&#xD;
      sodium lauryl sulfate, and sodium bicarbonate; 2) dentifrice containing 0.32% fluoride, 0.96%&#xD;
      zinc, arginine, poloxamer, glycerin, water, hydrated silica, sodium lauryl sulfate, and&#xD;
      sodium saccharin 3) dentifrice containing 0.454% stannous fluoride, water, sorbitol, hydrated&#xD;
      silica, glycerin, tetrasodium pyrophosphate, microcrystalline cellulose, and xanthan gum .&#xD;
&#xD;
      The interventions will be compared to each other. ICU group (n=52)- two interventions with&#xD;
      different oral antimicrobial solutions (26 patients in each intervention): 1) 0.12%&#xD;
      chlorhexidine solution (Colgate Periogard®); 2) 1.5% hydrogen peroxide solution plus 0.12%&#xD;
      chlorhexidine solution (Colgate Peroxyl® followed by Colgate Periogard®).&#xD;
&#xD;
      The interventions will be compared to each other.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 11, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Actual">December 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of SARS-CoV-2 load in the oral mucosa and saliva</measure>
    <time_frame>1 hour</time_frame>
    <description>Reduction of SARS-CoV-2 load in the oral mucosa and saliva measured by viral fold-reduction and viral quantitation</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">202</enrollment>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>Colgate Periogard and Peroxyl®</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients hospitalized in the ICU with orotracheal intubation or negative pressure room - will undergo antisepsia of the oral mucosa with 1.5% hydrogen peroxide solution, following by a 0.12% non-alcoholic chlorhexidine solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colgate Periogard®</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients hospitalized in the ICU with orotracheal intubation or negative pressure room - will undergo antisepsia of the oral mucosa with 0.12% non-alcoholic chlorhexidine solution;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colgate Peroxyl®</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients hospitalized in negative pressure rooms - will undergo antisepsia of the oral mucosa with 1.5% hydrogen peroxide solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colgate Total 12®</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients hospitalized in negative pressure rooms - will undergo antisepsia of the oral mucosa with 0.075% cetylpyridinium chloride associated with 0.28% zinc lactate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toothpaste with sodium monofluorophosphate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients hospitalized in negative pressure rooms - will undergo brushing with dentifrice containing only 1.1% fluoride, water, glycerin, cellulose, sodium lauryl sulfate, and sodium bicarbonate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toothpaste with sodium fluoride and zinc</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients hospitalized in negative pressure rooms - will undergo brushing with dentifrice containing 0.32% fluoride, 0.96% zinc, arginine, poloxamer, glycerin, water, hydrated silica, sodium lauryl sulfate, and sodium saccharin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toothpaste with tin fluoride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients hospitalized in negative pressure rooms - will undergo brushing with dentifrice containing 0.454% stannous fluoride, water, sorbitol, hydrated silica, glycerin, tetrasodium pyrophosphate, microcrystalline cellulose, and xanthan gum</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Colgate Periogard® mouthwash</intervention_name>
    <description>Patients will be submitted to antisepsia of the oral mucosa with Colgate Periogard® mouthwash</description>
    <arm_group_label>Colgate Periogard and Peroxyl®</arm_group_label>
    <arm_group_label>Colgate Periogard®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Colgate Peroxyl® mouthwash</intervention_name>
    <description>Patients will be submitted to antisepsia of the oral mucosa with Colgate Peroxyl® mouthwash</description>
    <arm_group_label>Colgate Periogard and Peroxyl®</arm_group_label>
    <arm_group_label>Colgate Peroxyl®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Colgate Total® Mouthwash</intervention_name>
    <description>Patients will be submitted to antisepsia of the oral mucosa with Colgate Total® Mouthwash</description>
    <arm_group_label>Colgate Total 12®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Toothpaste with sodium monofluorophosphate</intervention_name>
    <description>Patients will be submitted to brushing with toothpaste with sodium monofluorophosphate</description>
    <arm_group_label>Toothpaste with sodium monofluorophosphate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Toothpaste with sodium fluoride and zinc</intervention_name>
    <description>Patients will be submitted to brushing with toothpaste with sodium fluoride and zinc</description>
    <arm_group_label>Toothpaste with sodium fluoride and zinc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Toothpaste with tin fluoride</intervention_name>
    <description>Patients will be submitted to brushing with toothpaste with tin fluoride</description>
    <arm_group_label>Toothpaste with tin fluoride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients positive for SARS-CoV-2 using the RT-PCR method and requiring oral hygiene&#xD;
             care and other preventive and therapeutic dental procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pediatric patients, negative for SARS-CoV-2 by the RT-PCR method, exhibiting oral&#xD;
             ulcerations and other erosive lesions in the oral mucosa that contraindicate the use&#xD;
             of hydrogen peroxide, chlorhexidine and cetylpyridinium, patients who present bleeding&#xD;
             in the oral cavity. that prevents the collection of samples, patients who report a&#xD;
             history of allergy, irritations or other side effects derived from the use of these&#xD;
             substances, who do not adhere to the oral care protocols or those in which it is not&#xD;
             possible to perform these procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luciana Correa, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Debora H Douek, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Israelita Albert Einstein</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital israelita Albert Einstein</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05652-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2020</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Listerine</mesh_term>
    <mesh_term>Cetylpyridinium</mesh_term>
    <mesh_term>Fluorides</mesh_term>
    <mesh_term>Sodium Fluoride</mesh_term>
    <mesh_term>Fluorophosphate</mesh_term>
    <mesh_term>Tin Fluorides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

